Atherosclerosis, the gradual buildup of cholesterol-laden plaques inside artery walls, has long been understood as a disease of lipids. But cardiologists increasingly recognize chronic inflammation as its silent engine. Inflammatory markers predict cardiovascular risk independently of LDL cholesterol levels, and landmark trials of anti-inflammatory drugs have shown that taming the immune response can reduce cardiac events even when cholesterol is already controlled. The new study taps directly into this shift, asking whether a dietary compound could achieve what drugs have only partially delivered: suppressing the chronic, low-grade inflammation that drives plaque development before it starts.

The research team, led by scientists affiliated with Xiamen University, turned to low-density lipoprotein receptor knockout (LDLR−/−) mice, a classic model of human atherosclerosis in which the absence of the LDL receptor causes rapid accumulation of plasma LDL cholesterol and accelerated deposition in the arterial wall. Forty male mice, seven weeks old at arrival, were randomized into five groups after a week of adaptive feeding. Eight animals received a normal diet, while the remaining thirty-two were placed on a high-cholesterol diet containing just over 20% fat and 1.25% cholesterol. Three of these groups also received daily oral doses of 3′-SL at 40.5, 81.0, or 162.0 milligrams per kilogram of body weight, a range selected by allometric scaling from an established effective dose of free sialic acid and well below the compound’s reported no-observed-adverse-effect level of more than 2,000 milligrams per kilogram per day. The intervention continued for twelve weeks.

The results were striking and dose-dependent. Mice receiving 3′-SL showed significantly reduced lipid deposition in the aorta, visualized by Oil Red O staining of the full length of the vessel from the ascending arch to the iliac bifurcation. Blood chemistry told a parallel story: triglycerides fell in all intervention groups, LDL cholesterol declined in a clear dose–response relationship, and HDL—the “good” cholesterol—rose significantly. In the highest-dose group, total cholesterol also dropped. Meanwhile, oral glucose tolerance improved across the treatment groups, suggesting the compound’s benefits extended beyond lipid handling alone.

The inflammatory signature changed just as dramatically. High-cholesterol feeding elevated serum levels of pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-alpha (TNF-α). Supplementation with 3′-SL reversed this pattern, significantly lowering IL-6 and IL-1β across intervention groups, reducing TNF-α at medium and high doses, and boosting the anti-inflammatory cytokine IL-10. Because IL-6 and IL-1β are independently associated with elevated cardiovascular risk in human studies, this cytokine shift represents a potentially meaningful cardioprotective change, not merely a biochemical curiosity.

To understand how a milk sugar could accomplish all this, the investigators deployed a multi-omics arsenal: 16S rDNA sequencing of colon contents to map the gut microbiota, RNA sequencing of colonic tissue to capture transcriptional changes, and ultra-high-performance liquid chromatography–tandem mass spectrometry to profile the colonic metabolome. Using the medium-dose group as the representative cohort for mechanistic analysis, they found that 3′-SL substantially reshaped the microbial ecosystem. The abundance of Firmicutes—a phylum that expanded under the high-cholesterol diet—fell, while Verrucomicrobiota and Bacteroidetes rose, correcting the Firmicutes-to-Bacteroidetes ratio that has been repeatedly linked to obesity, metabolic disease, and atherosclerosis. At the genus level, the beneficial microbe Akkermansia expanded notably.

Akkermansia muciniphila has earned a reputation as an “intestinal guardian” in the microbiome literature. It feeds on the mucus layer lining the gut, stimulates the expression of tight junction proteins such as Occludin and Claudin-1, and releases outer membrane vesicles that reinforce the epithelial barrier. A sturdier barrier means fewer microbial endotoxins leaking into the bloodstream—an important source of the systemic inflammation that stokes arterial damage. Akkermansia also promotes short-chain fatty acid production, which dampens inflammatory signaling through G protein-coupled receptors on macrophages and intestinal epithelial cells, inhibiting the NF-κB pathway and reducing IL-6 secretion. Consistent with these mechanisms, the researchers observed that microbial correlations with serum IL-1β weakened after intervention while correlations with anti-inflammatory IL-10 strengthened, and the gut microbial structure of treated mice shifted toward that of the normal-diet controls.

The transcriptomic and metabolomic data added a deeper layer of mechanistic detail. Colonic tissue from treated mice showed differential expression of genes involved in immune regulation and lipid metabolism, including Ccl2, Il2ra, Kng1, and the complement component gene C6. Differential metabolites—ranging from lipid species to vitamin D derivatives and amino acid compounds—showed significant correlations with these immune- and cardiovascular-related genes. Among the findings, one molecule stands out as the linchpin of the study: Ccl2, better known as monocyte chemoattractant protein-1 (MCP-1). This chemokine recruits monocytes and macrophages into the subendothelial space of artery walls, the critical initiating step in foam cell formation and plaque development. The researchers found that 3′-SL suppressed Ccl2 expression, suggesting that gut-derived, anti-inflammatory metabolites entering the circulation may directly throttle the recruitment of inflammatory cells into the vasculature. Changes in Kng1 hint at additional benefits through the kinin system—potentially improving vascular tone and endothelial function—while effects on C6 suggest reduced complement-mediated damage to the endothelium via the membrane attack complex.

Taken together, the data sketch a coherent causal chain the authors call the “gut-immune-cardiovascular axis.” A high-cholesterol diet disrupts the gut microbiome, weakening the intestinal barrier and activating mucosal immune cells that seed systemic inflammation. 3′-SL, arriving intact in the colon after passing through the small intestine, feeds beneficial bacteria, restores microbial balance, strengthens the barrier, and recalibrates the metabolite pool. Those metabolites and immune signals then converge on the vascular wall, where reduced MCP-1 expression means fewer monocytes infiltrating the artery lining and fewer plaques taking root. The study’s integrated pathway analysis showed that the top enriched KEGG pathways among differential genes and metabolites involved immune regulation, inflammatory response, energy metabolism, lipid metabolism, and hormone synthesis—all processes implicated in the transition from metabolic stress to arterial disease.

The findings arrive amid growing enthusiasm for human milk oligosaccharides as functional food ingredients. 3′-SL is already recognized as safe by the U.S. FDA and approved as a novel food in the European Union, and a clinical trial in dyspeptic patients with Helicobacter pylori infection found doses up to 20 grams per day for four weeks to be well tolerated. Previous work has suggested the sugar can promote the growth of anti-inflammatory bacteria such as Faecalibacterium prausnitzii and Blautia in fecal communities from pediatric Crohn’s disease patients, and that it synergizes with Bifidobacterium infantis to alleviate intestinal inflammation through cross-feeding mechanisms that generate short-chain fatty acids. The current study extends this portfolio into cardiovascular territory, providing what the authors describe as robust preclinical evidence for gut-microbiota-targeted nutritional intervention against atherosclerosis.

Still, the researchers are careful about the limits of their work. The experiment used only male mice, leaving open whether hormonal cycles in females might alter the response, since estrogen and progesterone influence lipid metabolism, inflammation, and microbiome composition. The multi-omics analysis revealed correlations, not proven causation; future experiments such as fecal microbiota transplantation would be needed to establish that the reshaped microbiome itself drives the cardioprotection. Dosing also remains unresolved for humans—the mouse doses used translate to roughly 6.5 to 26 grams per day for a 60-kilogram adult by allometric scaling, and no clinical trials have yet tested 3′-SL for cardiovascular prevention. Patients with inflammatory bowel disease, whose permeable and inflamed guts may respond differently, warrant particular caution and dedicated trials before supplementation could be recommended.

Even with those caveats, the study marks a compelling proof of concept: a molecule designed by evolution to nourish infant guts may also defend adult arteries. As the global burden of atherosclerotic cardiovascular disease continues to climb, and as statins leave a residual inflammatory risk untouched in millions of patients, the idea that a prebiotic sugar could intercept the disease at its immunological source—via the gut—is precisely the kind of accessible, food-based strategy that prevention medicine has been searching for. The next step, translating the gut-immune-cardiovascular axis from mouse models to human trials, will determine whether breast milk’s lesser-known sugar becomes a genuine weapon against heart disease.

At the core of this evolving understanding is the concept of resilience. Initially, inflammation serves as a mechanism designed to promote healing. It responds to emergency cues—be they environmental insults or intrinsic age-related degradation—by engaging a multitude of cellular and molecular strategies aimed at repairing damage. This resilience mechanism is critical, particularly in the context of age-associated wear and tear. Over the decades, as cellular and tissue structures suffer incremental harm, the traditional portrayal of inflammation as a villain requires reevaluation, as it often initiates communication and healing processes aimed at safeguarding cardiovascular integrity.

The shift in perspective doesn’t stop at inflammation merely serving a protective function; it also underscores the potential for dysregulation to occur. As individuals age, the very mechanisms that initially foster resilience can begin to falter. This disruption can transform protective inflammation into a self-perpetuating cycle of damage that exacerbates tissue degradation rather than ameliorating it. Such maladaptive responses can culminate in a broad spectrum of cardiovascular disorders, including atherosclerosis, where excessive inflammation promotes plaque formation and subsequent arterial blockages.

Atherosclerosis serves as an exemplary model for illustrating the downsides of inflammation. In this condition, the immune system’s robust response to vascular injury can paradoxically worsen arterial health. Macrophages and other immune cells infiltrate damaged arterial walls, leading to further accumulation of lipids and inflammatory mediators. This cascade culminates in the formation of fibrous plaques, which can narrow blood vessels and even lead to thrombosis. Understanding how these inflammatory processes transpire in the context of age and cumulative damage is crucial for shaping effective therapies and prevention strategies.

In conjunction with atherosclerosis, age-related impairment of tissue perfusion offers another dimension to the discussion. As individuals grow older, the capability of tissues to receive adequate blood supply diminishes, often due to structural changes within blood vessels. These changes may be driven by inflammatory processes that not only degrade vascular health but also reduce the ability of tissues to recover from stress. The interplay between inflammation and perfusion further emphasizes that resolving CVD requires recognizing both the inflammatory landscape and the intricate balance between supply and demand within cardiovascular tissues.

Moreover, this paradigm prompts a deeper investigation into the molecular underpinnings of inflammation, particularly those related to aging. Research has identified specific biomarkers and molecular debris associated with cellular aging that instigate inflammatory cascades. Senescent cells, for example, can secrete pro-inflammatory cytokines, altering the tissue environment and perpetuating the cycle of inflammation and damage. This insight provides an exciting opportunity for interventions tailored to target the root causes of inflammation, potentially revolutionizing CVD prevention and treatment.

Mechanistically, the relationship between aging and inflammation can be dissected into several biological processes. One pivotal aspect is the accumulation of cellular damage over time, which manifests as DNA or protein damage, oxidative stress, and mitochondrial dysfunction. These forms of molecular damage are recognized as triggers for inflammatory responses, transforming a once-resilient system into one that enkindles chronic inflammation. Understanding these underlying mechanisms not only elucidates the intricacies of CVD pathophysiology but also offers a pathway for innovative therapeutic strategies.

The significance of these insights cannot be overstated in an aging population, where the prevalence of cardiovascular diseases is on an upward trajectory. By emphasizing the dual role of inflammation as both a defender and a potential saboteur, we can look toward targeted prevention strategies that focus on enhancing the body’s resilience against molecular damage. This may encompass lifestyle interventions, pharmacological therapies, and even advanced technologies aimed at directly repairing molecular damage, thus interrupting the cycle of inflammation before it spirals into pathology.

Integration of proteomic data from large population studies strengthens this evolving narrative by illustrating tangible correlations between molecular damage, inflammation, and cardiovascular outcomes. Such data serves to support the concept that inflammation should not be viewed in isolation but as part of a broader biological landscape characterized by ongoing tissue challenges. This multifactorial approach provides a more complete understanding of cardiovascular health and may lead to broader applications across various chronic conditions where inflammation plays a critical role.

As we navigate this new understanding of inflammation in cardiovascular disease, the emphasis on recognizing the subtle interactions between resilience, molecular damage, and inflammatory pathways becomes pivotal. Importantly, this multidimensional perspective compels us to acknowledge that the future of cardiovascular health lies in targeted interventions aimed at fostering healthier aging processes, mitigating chronic inflammatory responses, and addressing the molecular underpinnings of CVD.

Culminating in a robust synthesis of these findings, it is evident that chronic inflammation represents both a crucial player and a complex challenge within the cardiovascular landscape. As researchers continue to peel back the layers of this multifaceted relationship, the opportunity arises to translate these insights into actionable medical advancements. The quest for enhanced treatment modalities and preventive strategies centered around molecular damage and inflammation offers a promising horizon for combating the epidemic of cardiovascular diseases that disproportionately afflict aging populations.

With these revelations, it is essential for clinicians and researchers alike to incorporate the knowledge about inflammation and the aging process into their frameworks for understanding and addressing cardiovascular diseases. Embracing this new paradigm will not only foster a deeper comprehension of the intricate dynamics at play in CVD but also inspire innovative approaches to reduce the burden of these life-altering conditions in our rapidly aging society.

Understanding the dialogue between inflammation and cardiovascular disease encourages a more holistic view of health, emphasizing the importance of addressing the root causes of chronic inflammation rather than merely focusing on symptomatic treatments. It prompts the medical community to consider lifestyle factors that promote resilience against molecular damage, from dietary choices to physical activity, and to develop therapies with a focus on restoring balance within the body’s inflammatory responses. The future landscape of cardiovascular disease management is poised to embrace this complexity, ultimately working towards a healthier and more resilient aging demographic.

In conclusion, chronic inflammation’s role in cardiovascular disease symbolizes a crucial juncture within medical research and therapeutic development. As we refine our understanding of this intricate relationship, adopting a strategic and informed approach regarding inflammation’s dual nature is paramount. The path forward with respect to cardiovascular health will require an integrative perspective that appreciates the delicate balance between resilience mechanisms and the molecular chaos that can precipitate disease progression.

Subject of Research: Inflammation and its relationship with cardiovascular disease, particularly in the context of aging.

Article Title: Molecular damage associated with ageing drives inflammation in cardiovascular disease.

Article References:

Herman, A.B., Candia, J., Wilson, D.M. et al. Molecular damage associated with ageing drives inflammation in cardiovascular disease.
Nat Rev Cardiol (2026). https://doi.org/10.1038/s41569-026-01253-3

Image Credits: AI Generated

DOI: 10.1038/s41569-026-01253-3

Keywords: Chronic inflammation, cardiovascular disease, aging, cellular damage, resilience mechanism, atherosclerosis, tissue perfusion, molecular pathways, proteomics, therapeutic strategies.